Because your best therapy needs to rely on the best data.
Bosch Healthcare Solutions has developed the first and only FeNO home measuring device for asthma patients: Vivatmo me .
What is Vivatmo me
Vivatmo me is the first and only FeNO measuring device for home use. It can support your asthma patients in actively managing their disease. In just a few seconds*, the handy breath analyzer measures an inflammatory marker in exhaled breath, known as the FeNO value.
The FeNO value gives an indication of the degree of inflammation in the lungs at a given moment. Regular measurements provide you with important information about the progression of respiratory inflammation and can also be used as a basis for your medical therapy.
In the accompanying free Vivatmo app, the measured values can be digitally recorded in an asthma diary. The clear display of FeNO values, symptoms, peak flow values and pollen information enable you as a doctor to better monitor the degree of inflammation as well as possible asthma triggers.
Healthcare guidelines recommend FeNO measurement
In Germany, 3.5 million people receive medical treatment for asthma.1 According to the Global Asthma Network, asthma therapy focuses on controlling the symptoms of asthma and preventing asthma attacks.
One new method of asthma therapy monitoring is FeNO or NO measurement. This method uses a FeNO measuring device to measure a relevant inflammatory marker in the lungs in asthma patients’ exhaled breath. In the current addendum to the German Asthma Guideline2 , the determination of nitric oxide in breath exhalate (FeNO) is mentioned as part of the initial asthma diagnosis and repeated measurements are recommended.
What are the advantages of FeNO measurement at home for you and your patients?
Numerous scientific studies have demonstrated the value of in confirming the diagnosis and predicting the response to inhaled corticosteroids. What other advantages home FeNO measurement brings is currently the subject of clinical studies that have either just started or are in preparation. In the experience of physicians who are already using Vivatmo me with their patients, more frequent and regular FeNO measurements at home offer several advantages for asthma management and therapy planning. FeNO measurement enables consistent progress monitoring and early therapy optimization.3
- Regular FeNO measurements can help to reduce the incidence of acute asthma episodes.4
- Ease of use for asthma patients.
- Home measurement can improve compliance.
- Using the device can improve patients’ quality of life.
Increasing acceptance of digital solutions for self-monitoring
But what about the acceptance of digital applications among patients? According to a representative Civey online survey of 1,000 participants commissioned by Bosch Healthcare Solutions, 52 percent5 of all respondents diagnosed with asthma would want to monitor the course of their disease themselves using modern digital tools such as an app. At 62 percent5, the willingness to self-monitor is particularly high in the 40 to 49 age group. In contrast, almost 40 percent5 of respondents expressed reservations about cortisone in asthma therapy. These concerns even grow with increasing age.
What the specialist says
“By independently monitoring the measured values with Vivatmo me, asthmatics can regain self-determined control over their disease and make the ‘invisible enemy’, i.e. the inflammation in the lungs, more tangible. This is an important point for many asthmatics in better coping with and managing their disease.”
“The goal of modern asthma therapy is to avoid the lows and reduce symptoms over the long term. Monitoring the FeNO value helps to achieve this.”
*Adult mode: 10 sec. duration of measurement / child mode 6 sec. duration of measurement
1 “Asthma Health Atlas” of the Scientific Institute of the AOK health insurance fund (WIdO)
2 Buhl et al., 2021. Addendum to the German Asthma Guideline.
3 Hanania et al., 2018
4 Petsky et al., 2016
5 Civey online survey commissioned by Bosch Healthcare Solutions